PureTech Health Affiliates Gelesis and Vedanta Biosciences Announce Presentations at Digestive Disease Week
14 Mayo 2019 - 1:00AM
Business Wire
Gelesis presents first clinical data for GS500
prototype for chronic idiopathic constipation
Vedanta presents expanded Phase 1a/1b study
data of lead candidate, VE303, for recurrent Clostridium difficile
infection
PureTech Health plc (LSE: PRTC) (“PureTech Health”), an advanced
biopharmaceutical company developing novel medicines for
dysfunctions of the Brain-Immune-Gut (BIG) axis, today announced
that its affiliates Gelesis and Vedanta Biosciences will deliver
poster presentations of clinical data at Digestive Disease Week,
the world’s largest gathering of physicians, researchers, and
industry in the fields of gastroenterology, hepatology, endoscopy,
and gastrointestinal surgery.
Gelesis will present clinical data from a study of CSP01 (a
prototype of the investigational hydrogel candidate GS500, in
development for chronic idiopathic constipation (CIC)), which
demonstrated that CSP01 provided a statistically significant
reduction in colonic transit time in patients with CIC relative to
placebo.
Vedanta Biosciences will present expanded, longer-term data from
its successfully completed Phase 1a/1b study of VE303, the
company’s lead, orally-administered live biotherapeutic product
candidate for recurrent Clostridium difficile infection.
Details of the presentations are as follows:
GelesisSession Date and Time: May 19, 2019
from 12:00 PM to 2:00 PMSession Title: Constipation and
Other Functional Colonic SyndromesPresentation Title: CSP01,
A Novel Superabsorbent Hydrogel, Reduces Colonic Transit Time In
Chronic Idiopathic Constipation: Results From A Pilot Randomized,
Double-Blind, Placebo-Controlled TrialPoster Number:
Su1638
Vedanta BiosciencesSession Date and Time: May 20,
2019 from 12:00 PM to 2:00 PMPresentation Title: VE303, A
Live Biotherapeutic Product For Prevention Of
Recurrent Clostridioides Difficile (C.
Difficile) Infection. Preliminary Results Of A Phase 1,
Open-Label Healthy Volunteers Study Of Oral VE303 After
VancomycinPoster Number: Mo1955
About PureTech HealthPureTech Health (LSE: PRTC) is
an advanced biopharmaceutical company developing BIG medicines for
dysfunctions of the Brain-Immune-Gut axis. The Company has gained
deep insights into the connection between these systems and the
resulting role in diseases that have proven resistant to
established therapeutic approaches. By harnessing this emerging
field of human biology, PureTech Health is developing new
categories of medicines with the potential to have great impact on
people with serious diseases.
PureTech Health is advancing a rich pipeline of innovative
therapies with an unbiased, non-binary, and capital efficient
R&D model across its affiliates and its internal labs.
PureTech’s affiliates include seven clinical-stage platforms,
including one product that has been cleared by the US Food and Drug
Administration (FDA) and a second product candidate that has been
filed with the FDA for review, and several other novel preclinical
programs. The PureTech Health pipeline includes ground-breaking
platforms and therapeutic candidates that were developed in
collaboration with some of the world’s leading experts.
PureTech’s internal research and development is centered on
tissue-selective immunomodulation for the treatment of oncology,
autoimmune, and CNS-related disorders, with a near-term focus on
targeting newly-discovered, foundational immunosuppressive
mechanisms in oncology and novel approaches that harness the
lymphatic infrastructure.
For more information, visit www.puretechhealth.com or
connect with us on Twitter @puretechh.
Forward Looking StatementThis press release contains
statements that are or may be forward-looking statements, including
statements that relate to the company's future prospects,
developments and strategies. The forward-looking statements are
based on current expectations and are subject to known and unknown
risks and uncertainties that could cause actual results,
performance and achievements to differ materially from current
expectations, including, but not limited to, those risks and
uncertainties described in the risk factors included in the
regulatory filings for PureTech Health plc. These forward-looking
statements are based on assumptions regarding the present and
future business strategies of the company and the environment in
which it will operate in the future. Each forward-looking statement
speaks only as at the date of this press release. Except as
required by law and regulatory requirements, neither the company
nor any other party intends to update or revise these
forward-looking statements, whether as a result of new information,
future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190513005892/en/
InvestorsAllison Mead Talbot+1 617 651
3156amt@puretechhealth.comUS mediaTom Donovan+1 857 559
3397tom@tenbridgecommunications.com
Puretech Health (LSE:PRTC)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Puretech Health (LSE:PRTC)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024